Pasteurized Akkermansia Muciniphila MucT and Weight Loss Maintenance

Key Takeaways

• MucT was associated with less body-weight regain than placebo during the maintenance phase.
• The MucT group finished maintenance with greater net weight loss from baseline.
• Baseline Akkermansia spp. abundance was associated with cardiometabolic response to MucT, and no serious treatment-related adverse events were observed.

In adults with overweight or obesity, daily pasteurized Akkermansia muciniphila MucT was associated with less weight regain than placebo during a 24-week maintenance phase after diet-induced weight loss. The comparison began after participants had already reduced body weight through a structured low-energy diet phase. From baseline to the end of maintenance, the active group also had 3.1-kg greater net weight loss. The randomized comparison was reported in a Nature Medicine trial testing whether a microbiome-based supplement could alter post-diet weight trajectories during structured maintenance. The study was designed to assess weight-loss maintenance after an initial reduction had already been achieved.

The randomized controlled trial enrolled 90 adults with overweight or obesity into a two-stage protocol that separated initial weight reduction from maintenance testing. All participants first completed an 8-week low-energy diet and had to achieve at least 8% weight loss before randomization. They were then assigned to a 24-week healthy ad libitum diet with daily supplementation of pasteurized Akkermansia muciniphila MucT or placebo. The primary outcome was body-weight change during the maintenance period, and the study was registered as ClinicalTrials.gov identifier NCT05417360. The design measured whether the intervention affected weight course after an initial successful diet phase.

At the end of maintenance, mean body-weight regain was 1.2 ± 0.7 kg with MucT and 3.2 ± 0.4 kg with placebo, with P = 0.012. Investigators also found greater net weight loss from baseline to the end of maintenance in the MucT group, reported as 3.1 ± 0.7 kg with P = 0.009. The placebo group regained more of the earlier diet-induced loss, whereas the MucT group retained more of that loss through follow-up. These were reported as separate measures of maintenance-phase regain and overall change from study start to the end of follow-up. The between-group difference was evident at the end of maintenance.

Researchers also observed that initial Akkermansia spp. abundance was associated with cardiometabolic response to MucT during follow-up. This baseline feature was presented as an association rather than a validated predictor of benefit. No serious adverse events related to treatment were observed during the study period. The authors also cited the relatively short-term intervention and the absence of groups receiving modified MucT strains lacking active components as limitations. These points define the reported scope without extending the findings beyond the studied 24-week maintenance period.